Mark Sheptoff Financial Planning LLC decreased its stake in Pfizer Inc. (NYSE:PFE) by 4.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,636 shares of the biopharmaceutical company’s stock after selling 2,062 shares during the period. Pfizer comprises about 1.0% of Mark Sheptoff Financial Planning LLC’s holdings, making the stock its 26th largest holding. Mark Sheptoff Financial Planning LLC’s holdings in Pfizer were worth $1,522,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of the stock. Janus Henderson Group PLC raised its stake in shares of Pfizer by 243.5% during the second quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock valued at $442,574,000 after acquiring an additional 9,339,749 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Pfizer by 2.3% during the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after acquiring an additional 9,239,499 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Pfizer during the second quarter valued at $268,389,000. Canada Pension Plan Investment Board raised its stake in shares of Pfizer by 249.6% during the second quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock valued at $359,871,000 after acquiring an additional 7,649,416 shares during the last quarter. Finally, Longview Partners Guernsey LTD raised its stake in shares of Pfizer by 32.0% during the third quarter. Longview Partners Guernsey LTD now owns 24,369,672 shares of the biopharmaceutical company’s stock valued at $869,997,000 after acquiring an additional 5,901,100 shares during the last quarter. 69.87% of the stock is owned by institutional investors and hedge funds.

Pfizer Inc. (NYSE PFE) opened at $34.16 on Friday. Pfizer Inc. has a 52 week low of $31.67 and a 52 week high of $39.43. The firm has a market cap of $206,830.00, a price-to-earnings ratio of 9.70, a P/E/G ratio of 1.98 and a beta of 0.94. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 26.86%. The business had revenue of $13.70 billion during the quarter, compared to the consensus estimate of $13.67 billion. During the same quarter last year, the firm earned $0.47 earnings per share. Pfizer’s quarterly revenue was up .6% on a year-over-year basis. analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.98%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. Pfizer’s dividend payout ratio (DPR) is presently 38.64%.

Pfizer announced that its board has approved a share repurchase program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its stock is undervalued.

Several equities analysts have recently issued reports on the stock. BMO Capital Markets set a $43.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, February 5th. UBS Group set a $42.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, January 31st. Berenberg Bank set a $36.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, January 30th. Morningstar set a $38.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, January 30th. Finally, Goldman Sachs Group set a $36.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $39.45.

In other Pfizer news, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the sale, the executive vice president now directly owns 46,963 shares in the company, valued at $1,740,918.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now owns 103,458 shares of the company’s stock, valued at $3,827,946. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Mark Sheptoff Financial Planning LLC Reduces Position in Pfizer Inc. (PFE)” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.watchlistnews.com/mark-sheptoff-financial-planning-llc-reduces-position-in-pfizer-inc-pfe/1856846.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.